Back to top
more

Horizon Pharma Public Limited Company (HZNP)

(Delayed Data from NSDQ)

$26.54 USD

26.54
1,058,972

+0.55 (2.12%)

Updated May 3, 2019 04:00 PM ET

After-Market: $26.52 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Is Horizon Pharma (HZNP) Poised for a Beat in Q1 Earnings?

Horizon Pharma plc (HZNP) is scheduled to report first-quarter 2017 results before the opening bell on May 8.

    What's in Store for Mallinckrodt (MNK) This Earnings Season?

    Mallinckrodt plc (MNK) is set to report first-quarter fiscal 2017 results on May 8.

      Horizon (HZNP) Down 10.2% Since Earnings Report: Can It Rebound?

      Horizon (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

        Can Horizon Pharma (HZNP) Be a Great Stock for Value Investors?

        Horizon Pharma (HZNP) can Be a Great Stock for Value Investors on the back of its strong key value statistics.

          Horizon (HZNP) Misses on Earnings in Q4, View Disappoints

          Horizon Pharma's (HZNP) fourth quarter results were disappointing with the company missing on both top- and bottom line estimates. Moreover, the guidance for 2017 also fell short of expectations.

            Ekta Bagri headshot

            Horizon Pharma (HZNP) Misses Q4 Earnings & Revenues

            Horizon Pharma???s fourth-quarter 2016 earnings missed expectations.

              Horizon (HZNP) Q4 Earnings: Stock Likely to Disappoint?

              Horizon Pharma plc (HZNP) is scheduled to report fourth-quarter 2016 results on Feb 27, before the opening bell.

                Horizon's Rare Disease Drug Quinsair Launched in Canada

                Horizon Pharma plc (HZNP) announced the availability of Quinsair (levofloxacin inhalation solution) in Canada for the management of chronic pulmonary infections.

                  Horizon (HZNP) Stock Sinks, Friedreich's Ataxia Study Fails

                  Horizon Pharma (HZNP) has decided to discontinue the development of Actimmune for Friedreich's ataxia after a phase III study failed to meet key endpoints.

                    Sheraz Mian headshot

                    Top Research Reports for 29th November, 2016

                    Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth (UNH), 21st Century Fox (FOXA) and Sanofi (SNY).

                      Tracey Ryniec headshot

                      This Week's Top Value Stocks: (HZNP) (DF)

                      Value stock strategist, Tracey Ryniec, profiles Horizon Pharma Plc (HZNP) and Dean Foods (DF).

                        Kevin Matras headshot

                        PEG Ratio vs. the P/E Ratio

                        Kevin Matras compares the PEG ratio to the P/E ratio and shows how to use them both for finding classically undervalued stocks with market beating growth rates. Highlighted stocks include SIMO, ORBK, NTI, HZNP and AIRM.

                          Kevin Matras headshot

                          A Company's First Profit Can Mean Big Profits to Investors

                          Kevin Matras screens for companies showing their 'first' profit, and explains why they are ones to watch. Highlighted stocks include POZN, XCRA, NM, KEM and HZNP.